Benzinga | Mar 15, 2021 07:06AM EDT

Tonix Pharma Announces 50% Enrollment in its Second Phase 3 Study of TNX-102 to Treat Fibromyalgia

"We believe that achieving this milestone keeps us on plan for the anticipated release of interim results from RALLY in the third quarter and topline data in the fourth quarter of this year," said Tonix's President and Chief Executive Officer, Seth Lederman, M.D. "If the topline results are positive, we expect to be in a position to submit a New Drug Application (NDA) for TNX-102 SL for fibromyalgia to the U.S. Food and Drug Administration (FDA) in 2022."